SIETES :: 92692 citas

Resultados de la búsqueda por Moore,TJ

1.

Moore TJ, Mattison DR. Assessment of patterns of potentially unsafe use of zolpidem. JAMA Intern Med 2018;178:septiembre. [Ref.ID 102884]

2.

Moore TJ, Hanzhe Z, Anderson G, Alexander C. Estimated costs of pivotal trials for novel therapeutic agents approved by the US Food and Drug Administration, 2015-2016. JAMA Intern Med 2018:24 de septiembre. [Ref.ID 102831]

3.

Woloshin S, Schwartz LM, White B, Moore TJ. The fate of FDA postapproval studies. N Engl J Med 2017;377:1114-7. [Ref.ID 102072]

4.

Moore TJ, Furberg CD, Mattison DR, Cohen MR. Completeness of serious adverse drug event reports received by the US Food and Drug Administration in 2014. Pharmacoepidemiol Drug Saf 2016;25:713-8. [Ref.ID 100396]

5.

Moore TJ, Furberg CD. Electronic health data for postmarket surveillance: a vision not realized. Drug Saf 2015;38:601-10. [Ref.ID 99852]

6.

Moore TJ, Glenmullen J, Mattison DR. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern Med 2014;174:1930-3. [Ref.ID 98401]

7.

Moore TJ, Cohen MR, Mattison DR. Dabigatran, bleeding, and the regulators. BMJ 2014;349:g4517. [Ref.ID 98146]

8.

Moore TJ, Furberg CD. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US Food and Drug Administration. The class of 2008. JAMA Intern Med 2014;174:90-5. [Ref.ID 96996]

9.

Moore TJ. New drug: caution indicated: Comment on "New drugs and safety". Arch Intern Med 2012;1721:1681-2. [Ref.ID 94147]

10.

Moore TJ, Furberg CD, Glenmullen J, Maltsberger JT, Singh S. Suicidal behavior and depression in smoking cessation treatments. PLOS ONE 2011;6:e27016. [Ref.ID 91685]

11.

Vaithianathan R, Hockey PM, Moore TJ, Bates DW. Iatrogenic effects of COX-2 inhibitors in the US population: findings from the Medical Expenditure Panel Survey. Drug Saf 2009;32:335-43. [Ref.ID 85765]

12.

Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLOS Medicine 2008;5:e45. [Ref.ID 82220]

13.

Moore TJ, Cohen MR, Furberg CD. Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Arch Intern Med 2007;167:1752-9. [Ref.ID 81063]

14.

Moore TJ, Walsh CS, Cohen MR. Reported adverse event cases of methemoglobinemia associated with benzocaine products. Arch Intern Med 2004;164:1192-6. [Ref.ID 70423]

15.

Vollmer WM, Sacks FM, Ard J, Appel LJ, Bray GA, Simons-Morton DG, Conlin PR, Svetkey LP, Erlinger TP, Moore TJ, Karanja N, for the DASH-Sodium Trial Collaborative Research Group. Effects of diet and sodium intake on blood pressure: subgroup analysis of the DASH-Sodium Trial. Ann Intern Med 2001;135:1019-28. [Ref.ID 60606]

16.

Moore TJ, Psaty B M, Furberg CD. Time to act on drug safety. JAMA 1998;279:1571-3. [Ref.ID 38412]

17.

Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM, Cutler JA, Windhauser MM, Lin P-H, Karanja N, for the DASH Collaborative Research Group. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med 1997;336:1117-24. [Ref.ID 31672]